Worth reading
64In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
24466104
SharesWording
Conditional
How definitive the wording is.This transaction
This tender offerCounterpartyMEDIPAL HOLDINGS CORPORATION
Disclosing companyPALTAC CORPORATION
The voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.
TimelineThe spacing between the points is proportional to the actual number of days.
Consideration and expenses
Type of ConsiderationCash
Tender offer price¥6,650 per common share
Minimum number of shares to be purchased8,676,100 shares
Tender offer periodFrom 12 May 2026 to 7 July 2026 (41 business days)
Procedures and assumptions
Management structure after acquisitionA series of squeeze-out procedures will be carried out to make the tender offeror the sole shareholder of the target company. If the squeeze-out procedures are completed, the target company's shares will be delisted following the prescribed procedures. The target company plans to promptly disclose the subsequent procedures once they have been determined.
| Item | Details |
|---|---|
| Transaction name | This tender offer |
| Counterparty name | MEDIPAL HOLDINGS CORPORATION |
| Name of the Subject Company | PALTAC CORPORATION |
| Type of Consideration | Cash |
| Tender offer price | ¥6,650 per common share |
| Minimum number of shares to be purchased | 8,676,100 shares |
| Tender offer period | From 12 May 2026 to 7 July 2026 (41 business days) |
| Number of shares acquired | 24,466,104 shares (number of voting rights: Not disclosed) |
| Voting rights ownership percentage | Before 52.40％ → after 92.64％ |
| Date of board resolution | 11 May 2026 |
| Execution Date / Effective Date | 14 July 2026 (settlement commencement date) |
| Management structure after acquisition | A series of squeeze-out procedures will be carried out to make the tender offeror the sole shareholder of the target company. If the squeeze-out procedures are completed, the target company's shares will be delisted following the prescribed procedures. The target company plans to promptly disclose the subsequent procedures once they have been determined. |
Items this document does not state (20)
Business Description of the Subject CompanyLocation of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceMerger ratio/share exchange ratioFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Impact on Business PerformanceContract DateValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to Execution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This document explains the results of the tender offer and the subsequent squeeze-out procedures. It states that the reasons for the transaction remain unchanged from those described in the notice regarding the commencement of the tender offer published on 11 May 2026, and does not provide further details.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.